PCBP2 and familial pancreatic carcinoma: Overall, our data strongly support the hypothesis that a combination treatment with the CCP/PCBP2 siRNA nanocomplex and chemotherapy using gemcitabine should be considered a promising strategy for pancreatic cancer therapy due to its beneficial modulation of the fibrotic stroma.